Warning: The NCBI web site requires JavaScript to function. more...
Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders.
Huckans MS, Loftis JM, Blackwell AD, Linke A, Hauser P.
Subst Abuse Treat Prev Policy. 2007 Jan 12;2:4.
Related citations
Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.
Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.
Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
Dollarhide AW, Loh C, Leckband SG, Endow-Eyer R, Robinson S, Meyer JM.
J Clin Gastroenterol. 2007 Mar;41(3):322-8.
Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.
Lo Re V 3rd, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R.
Ann Intern Med. 2011 Sep 20;155(6):353-60.
Integrated hepatitis C virus treatment: addressing comorbid substance use disorders and HIV infection.
Huckans MS, Blackwell AD, Harms TA, Indest DW, Hauser P.
AIDS. 2005 Oct;19 Suppl 3:S106-15.
Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
Andriulli A, Cursaro C, Cozzolongo R, Iacobellis A, Valvano MR, Mangia A, Minerva N, Bacca D, Stanzione M, Scuteri A, Montalto G, Andreone P.
J Viral Hepat. 2009 Jan;16(1):28-35. Epub 2008 Aug 28.
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.
Clin Infect Dis. 2008 Nov 15;47(10):1260-9.
Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders.
Matthews AM, Huckans MS, Blackwell AD, Hauser P.
Bipolar Disord. 2008 Mar;10(2):266-70.
Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.
Braga EL, Lyra AC, Nascimento L, Netto E, Kalabrik L, Lyra LG.
Arq Gastroenterol. 2006 Oct-Dec;43(4):275-9.
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders.
Chainuvati S, Khalid SK, Kancir S, Shea M, Edwards J, Sernyak M, Wongcharatrawee S, Garcia-Tsao G.
J Viral Hepat. 2006 Apr;13(4):235-41.
Infection with hepatitis C virus genotype 4 in the United States.
Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM.
J Clin Gastroenterol. 2004 Jan;38(1):68-71.
Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.
J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. Epub 2008 Apr 19.
Interferon beta 1a versus interferon beta 1a plus ribavirin for the treatment of chronic hepatitis C in Chinese patients: a randomized, placebo-controlled trial.
Han Q, Liu Z, Kang W, Li H, Zhang L, Zhang N.
Dig Dis Sci. 2008 Aug;53(8):2238-45. Epub 2007 Dec 13.
The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C.
Nattermann J, Vogel M, Nischalke HD, Danta M, Ahlenstiel G, Michalk M, Sauerbruch T, Rockstroh JK, Spengler U; Kompetenznetz HIV/AIDS.
AIDS. 2008 Jul 11;22(11):1287-92.
Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
J Med Virol. 2008 Aug;80(8):1363-9.
Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon.
Boulestin A, Kamar N, Sandres-Sauné K, Legrand-Abravanel F, Alric L, Vinel JP, Rostaing L, Izopet J.
J Med Virol. 2006 Mar;78(3):365-71.
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.
Antivir Ther. 2008;13(4):511-7.
Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Raziorrouh B, Jung MC, Schirren CA, Loehe F, Thiel M, Nitschko H, Diepolder H, Ulsenheimer A, Heeg M, Zachoval R, Gruener NH.
Eur J Gastroenterol Hepatol. 2008 Aug;20(8):778-83.
Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kanamori A, Atsumi H, Takagi M, Nakano S, Arakawa T, Fujimori M.
J Med Virol. 2009 Aug;81(8):1354-62.
Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C.
J Viral Hepat. 2008 Jul;15(7):482-9. Epub 2008 Jan 23.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on